The estimated Net Worth of Michael D Wortley is at least $23.1 Million dollars as of 15 August 2023. Mr. Wortley owns over 1,205 units of Reata Pharmaceuticals Inc stock worth over $8,566,464 and over the last 9 years he sold RETA stock worth over $12,461,207. In addition, he makes $2,033,950 as Executive Vice President and Chief Legal Officer at Reata Pharmaceuticals Inc.
Sign up
Mr. Wortley RETA stock SEC Form 4 insiders trading
Michael has made over 6 trades of the Reata Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,205 units of RETA stock worth $203,585 on 15 August 2023.
The largest trade he's ever made was selling 51,429 units of Reata Pharmaceuticals Inc stock on 11 November 2020 worth over $9,224,820. On average, Michael trades about 3,339 units every 65 days since 2015. As of 15 August 2023 he still owns at least 49,701 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Mr. Wortley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Wortley biography
Michael D. Wortley serves as Executive Vice President, Chief Legal Officer of the Company. Prior to joining Reata, Prior to joining Reata, Mr. Wortley was an attorney at Vinson & Elkins LLP from 1995 to March 2015, serving in various capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office, and, prior to 1995, at Johnson & Wortley, P.C., serving as Chairman of the Board and President. He currently serves on the board of directors of Pioneer Natural Resources Company. Mr. Wortley earned a B.A. in Political Science from Southern Methodist University, a Master’s degree in Regional Planning from the University of North Carolina at Chapel Hill and a J.D. from Southern Methodist University Dedman School of Law.
What is the salary of Michael Wortley?
As the Executive Vice President and Chief Legal Officer of Reata Pharmaceuticals Inc, the total compensation of Michael Wortley at Reata Pharmaceuticals Inc is $2,033,950. There are 3 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.
How old is Michael Wortley?
Michael Wortley is 72, he's been the Executive Vice President and Chief Legal Officer of Reata Pharmaceuticals Inc since 2018. There are 1 older and 14 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
What's Michael Wortley's mailing address?
Michael's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.
Insiders trading at Reata Pharmaceuticals Inc
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy, and Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
What does Reata Pharmaceuticals Inc do?
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
What does Reata Pharmaceuticals Inc's logo look like?
Complete history of Mr. Wortley stock trades at Reata Pharmaceuticals Inc and Pioneer Natural Resources Co
Reata Pharmaceuticals Inc executives and stock owners
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Manmeet Soni,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
J. Warren Huff,
Chairman of the Board, President, Chief Executive Officer -
Colin Meyer,
Executive Vice President, Chief Research and Development Officer -
Michael Wortley,
Executive Vice President, Chief Legal Officer -
Dawn Bir,
Executive Vice President, Chief Commercial Officer -
Manmeet Singh Soni,
COO, CFO & Pres -
J. Warren Huff,
Chairman & CEO -
Dr. Colin J. Meyer M.D.,
Exec. VP & Chief Innovation Officer -
Michael D. Wortley,
Exec. VP & Chief Legal Officer -
Dawn Carter Bir,
Exec. VP & Chief Commercial Officer -
Jack Nielsen,
Independent Director -
William McClellan,
Independent Director -
William Rose,
Independent Director -
R. Kent McGaughy,
Independent Director -
Vineet Jindal,
Vice President, Corporate Communications and Strategy -
Martin Edwards,
Independent Director -
Seemi Khan,
Chief Medical Officer -
Andrea Loewen,
Vice President - Global Regulatory Affairs -
Kevin Johnston,
Chief Technical Officer, Vice President -
Steve Harman,
VP & Chief HR Officer -
Dakota Gallivan,
VP & Chief Healthcare Compliance Officer -
Dr. W. Christian Wigley Ph.D.,
Sr. VP & Chief Scientific Officer -
Bhaskar Anand,
VP & Chief Accounting Officer -
William Puffin Partners, L....,
-
Dennis K. Stone,
Director -
Elaine Castellanos,
VP, Chief Accounting Officer -
Holdings A/S Novo,
10% owner -
James Edward Bass,
Director -
James W Jr Traweek,
-
Inc Cpmg,
-
Inc. Abb Vie,
10% owner -
Keith Wayne Ward,
See Remarks -
William Rose Evelyn P.Edwar...,
-
William Puffin Partners, L....,
-
Antal Rohit Cpmg Inc Desai,
-
William Montrose Investment...,
-
William Charles Henry Rose ...,
-
William Puffin Partners, L....,
-
William Estate Of Edward W....,
-
Jason Douglas Wilson,
Executive VP of Operations -
Pharma Llcstapleton Craig R...,
-
Christy J. Oliger,
Director -
Shamim Ruff,
Director -
Bhaskar Anand,
SVP, Chief Accounting Officer -
Steven Ryder,
Director -
Samina Khan,
SVP, Chief Medical Officer -
Rajiv Patni,
EVP, Chief R&D Officer